Psoriatic Arthritis MedDRA version: 21.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859
Conditions
Interventions
Trade Name: Cosentyx
Product Name: Cosentyx
Pharmaceutical Form: Solution for injection
INN or Proposed INN: secukinumab
CAS Number: 1229022-83-6
Current Sponsor code: CAIN457ADE06
Other descriptive n
Sponsors
University of Liverpool
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient secukinumab treatment group: 20 patients with active psoriatic arthritis (fulfilling CASPAR criteria) affecting =2 peripheral joints (swollen and tender) that have not responded to at least one standard DMARDs 2. Healthy control group: 10 healthy control blood samples. The healthy controls will be recruited from staff at the University of Liverpool or Aintree University hospitals and who are not taking nor have taken over the preceding 6 months, any immunosuppressive agent including systemic corticosteroids and whose health is otherwise good. There will be an equal balance of males to females. Matching to biologic or DMARD controls is not required. The healthy controls will provide one sample of blood for neutrophil studies (as detailed above). All participants will be adult individuals who are: • Able to give informed consent • Aged over 18 years 1. In the case of PsA patients they will: a. All meet CASPAR criteria for diagnosis of PsA b. Be rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) negative at screening. c. Have had no prior exposure to biologic therapy d. Not have received parenteral glucocorticosteroids in the 6 weeks prior to the baseline assessment e. If taking oral glucocorticoids remain on a stable dose of =65 years) yes F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: 1. Active or chronic infection including mycobacterium tuberculosis, HIV, hepatitis B or C 2. Absence of active psoriatic arthritis 3. Patients who are starting anti-TNF therapy for treating PsA 4. Pregnancy and planning pregnancy: a) WOCBP who are unwilling or unable to use acceptable method to avoid pregnancy for study duration plus timeframe as specified in section 5.2.5. b) Women who are pregnant or breastfeeding c) Sexually active fertile men not using effective birth control if their partners are WOCBP. 5. Malignancy 6. Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process obtained within 3 months prior to Screening and evaluated by a qualified physician. 7. Patients with hyponaetraemia and nephrotic syndrome 8. Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor. 10. Use of any investigational drug and/or devices within 4 weeks before registration or a period of 5 half-lives of the investigational drug, whichever is longer. 11. Significant comorbidity that, in the opinion of the investigator, would impact on ability to participate 12. Any change in the dose of oral glucocorticosteroids or DMARDS in the prior 6 weeks prior to the Baseline visit or use of i.v. intramuscular or intra-articular glucocorticosteroid during the last 6 weeks prior to the enrolment visit. 13. Patients who have previously been treated with TNFa inhibitors (investigational or approved). 14. History of hypersensitivity to the study drug or its excipients or to drugs of similar classes. 15. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3,anti-CD19). 16. Active ongoing inflammatory diseases other than PsA that might confound the evaluation of the benefit of secukinumab therapy. 17. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine,cardiac, infectious or gastrointestinal conditions which in the opinion of the Investigator immunocompromise the patient and/or place the patient at unacceptable risk for participation in an immunomodulatory therapy. 18. Significant medical problems or diseases, including but not limited to the following: uncontrolled hypertension (= 160/95 mmHg), congestive heart failure (New York Heart Association status of class III or IV), uncontrolled diabetes. 19. History of clinically significant liver disease or liver injury as indicated by abnormal liver function tests (LFT) such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or serum bilirubin. The Investigator should be guided by the following criteria: a. Any single parameter may not exceed 2 x upper limit of normal (ULN). A single parameter elevated up to and including 2 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to enrolment/registration, to rule out laboratory error. b. If the total bilirubin concentration is increased above 2 x ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin. In any case, serum bilirubin should not exceed 1.6 mg/dL (27 µmol/L). 20. History of renal trauma, glomerulonephritis, or patients with 1 kidney only, or a serum creatinine level exceeding 1.5 mg/dL (132.6 µmol/L). 21. Screening total white blood cell (WBC) count < 3 000/µL, or platelets < 100 000/µL or neutrophils < 1 500/µL or hemoglobin < 8.5 g/dL (85 g/L).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: 1.To determine if neutrophil life span and function is associated with vitamin D concentration and VDR receptor expression in PsA patients, and 2.To explore whether vitamin D concentrations and VDR expression influence neutrophil lifespan and function in PsA patients before and after treatment with secukinumab. Exploratory Aims 1) To identify whether vitamin D status and levels of VDR expression are associated with development of PASI 75 and 90 responses for skin manifestations, ACR20 response for joint manifestations and achievement of PsARC in response to secukinumab in PsA, 2) To evaluate the clinical response of patients with psoriatic arthritis, treated with secukinumab using, NAPSI, PsARC, PASI 75 and 90 and ACR20 response criteria, 3) To evaluate the safety of patients treated with secukinumab in terms of adverse events (AE), serious adverse events (SAE), infections and serious infections, malignancies, acute injection site reactions and potential immunogenicity, and;Main Objective: We propose an open label pragmatic clinical and laboratory study designed to to determine the molecular effects of IL-17 and inhibition of IL-17 with secukinumab on neutrophil phenotype and lifespan changes over time. ;Primary end point(s): Neutrophil phenotype and lifespan change in function over time.;Timepoint(s) of evaluation of this end point: Assessments be completed at baseline, 1, 3, 6, 9 and 12-month follow up, together with any other unscheduled visits as indicated clinically | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1) To determine if neutrophil life span and function is associated with vitamin D concentration and VDR receptor expression in PsA patients. 2) To explore whether vitamin D concentrations and VDR expression influence neutrophil lifespan and function in PsA patients before and after treatment with secukinumab. ;Timepoint(s) of evaluation of this end point: Assessments be completed at baseline, 1, 3, 6, 9 and 12-month follow up, together with any other unscheduled visits as indicated clinically | — |
Countries
United Kingdom
Contacts
Public ContactTrial Co-ordinator
Liverpool Cancer Trials Unit
Outcome results
None listed